0000000000646660

AUTHOR

Maria Christina Cox

showing 2 related works from this author

Rituximab plus chemotherapy provides no clinical benefit in a peripheral T-cell lymphoma not otherwise specified with aberrant expression of CD20 and…

2020

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy. Only a few cases of PTCL with aberrant expression of B-cell antigens have been reported so far. This phenotypic aberrancy may lead to misdiagnosis as B-cell non-Hodgkin lymphomas and eventual inappropriate patient management, whereas in an accurately diagnosed PTCL, the presence of CD20 may appear as an appealing therapeutic target. In this setting, response to anti-CD20 monoclonal antibody in combination with chemotherapy has been poorly explored. We describe the case of a 59-year-old …

Oncologyperipheral t-cell lymphomamedicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryPeripheral T-cell lymphoma not otherwise specifiedCase ReportSettore MED/08 - Anatomia Patologicarituximab.03 medical and health sciences0302 clinical medicinerituximabimmune system diseasesInternal medicinehemic and lymphatic diseasesMedicineb-cell antigens; cd20; cd79a; peripheral t-cell lymphoma; rituximabCD20cd79aperipheral T-cell lymphomaB-cell antigenCD20lcsh:R5-920Chemotherapybiologybusiness.industryNot Otherwise Specifiedcd20CD79amedicine.diseaseCD79APeripheral T-cell lymphomaLymphomab-cell antigens030220 oncology & carcinogenesisbiology.proteinRituximablcsh:Medicine (General)business030215 immunologymedicine.drug
researchProduct

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

2007

Myeloid sarcoma ( MS) is a rare neoplasm whose knowledge is largely based on case reports and/or technically dated contributions. Ninety-two MSs in adulthood with clinical data available were evaluated both morphologically and immunohistochemically. Seventy-four cases were also studied by fluorescent in situ hybridization on tissue sections and/or conventional karyotyping on bone marrow or peripheral blood. Histologically, 50% of the tumors were of the blastic type, 43.5% either monoblastic or myelomonocytic and 6.5% corresponded to different histotypes. CD68/KP1 was the most commonly expressed marker (100%), followed by myeloperoxidase (83.6%), CD117 (80.4%), CD99 (54.3%), CD68/PG-M1 (51%)…

AdultGenetic MarkersMaleCancer ResearchPathologymedicine.medical_specialtyAdolescentLymphomaCD34BiologyTrisomy 8Translocation Geneticcytogeneticsmyeloid sarcoma; chloroma; FISH; cytogenetics; immunohistochemistry; prognosisFISHAntigens CDmyeloid sarcomamedicineMyeloid sarcomaHumansIn Situ Hybridization FluorescenceAgedAged 80 and overChromosome Aberrationsmedicine.diagnostic_testCytogeneticschloromaSarcomaHematologyMiddle Agedmedicine.diseaseTransplantationLeukemiaPhenotypeOncologyLeukemia MyeloidimmunohistochemistryFemaleprognosisSarcomaalpha interferonCD30 antigenCD34 antigenFluorescence in situ hybridization
researchProduct